Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099833 | 1.00 | HRH3 (0.42) | HRH3MEN1KMT2ASLC6A4SLC6A2 | |
| SCHEMBL13723937 | 0.87 | HRH3 (0.46) | HRH3SLC6A4SLC6A2SIGMAR1KCNH2 | |
| SCHEMBL13723347 | 0.87 | HRH3 (0.46) | HRH3SLC6A4SLC6A2SIGMAR1KCNH2 | |
| SCHEMBL4975855 | 0.84 | OPRD1 (0.44) | HRH3MEN1KMT2ASLC6A4SLC6A2 | |
| SCHEMBL4088960 | 0.84 | OPRD1 (0.44) | HRH3MEN1KMT2ASLC6A4SLC6A2 | |
| SCHEMBL4093973 | 0.84 | OPRD1 (0.44) | HRH3MEN1KMT2ASLC6A4SLC6A2 | |
| SCHEMBL27664992 | 0.80 | HRH3 (0.44) | HRH3MEN1KMT2ASLC6A4SLC6A2 | |
| SCHEMBL2315253 | 0.80 | MEN1 (0.58) | HRH3MEN1KMT2AOPRD1KCNH2 | |
| SCHEMBL2537196 | 0.80 | MEN1 (0.58) | HRH3MEN1KMT2AOPRD1KCNH2 | |
| SCHEMBL4146000 | 0.80 | MEN1 (0.58) | HRH3MEN1KMT2AOPRD1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | THPO, DPYD, TPMT | HRH3 2328/4885MEN1 4695/4885KMT2A 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.